![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maelor | LSE:MLR | London | Ordinary Share | GB00B2QBY649 | ORD 70P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 100.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Maelor PLC 31 October 2007 Maelor plc 31 October 2007 Maelor plc (the "Company") New distribution agreement for OptiFlo(TM) Catheter Maintenance Solutions The Board of Maelor plc ("Maelor"; AIM:MLR), the specialist hospital medicines group, is pleased to announce the completion of a new five year agreement with Bard Limited (Bard) for distribution of the OptiFlo(TM) Catheter Maintenance Solutions. The agreement which covers the UK and Ireland continues the relationship between Bard and Maelor that has driven the growth of the OptiFlo(TM) Solutions to become the UK market leading urinary catheter maintenance solutions. Over the coming years Bard will continue to focus on further growing both the market for OptiFlo(TM) Solutions and its market share. This will be achieved through the continued education and support of community health care professionals in effective catheter management to maximise patient quality of life. Tim Wright, Chief Executive of Maelor plc, said: "With the focus of Maelor in the hospital specialist sector, this agreement with Bard aligns closely with our strategy of ensuring that our products which are outside our focus are leveraged through 1st class partnerships. The team at Bard have done an excellent job of commercialising OptiFlo(TM). Our two companies have formed a very positive working relationship and with the strength of Bard in both medical devices and urology we are confident that the relationship will continue on a very positive footing." Alan Whitcombe, European Marketing Director, Urology of Bard Limited, said: "We are very pleased to be able to continue our partnership with Maelor, who have provided us with outstanding technical and operational support as we have grown OptiFlo(TM). We see OptiFlo(TM) as a key product in our UK portfolio and look forward to working closely together as we continue to further develop and grow the brand" - Ends - OptiFlo(TM) is a trademark of C. R. Bard, Inc. or an affiliate. For further information, call: Tim Wright, Maelor plc - +44 (0) 1244 625150 Billy Clegg/Edward Westropp, Financial Dynamics - +44 (0) 207 831 3113 Matthew Hall/Sam Reynolds, Noble & Company - +44 (0) 207 7632200 This information is provided by RNS The company news service from the London Stock Exchange END NRABCBDGUGXGGRG
1 Year Maelor Chart |
1 Month Maelor Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions